Solid Biosciences Inc.

What they do

Solid Biosciences is a life sciences company advancing a portfolio of gene therapy candidates, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy. The company also develops genetic regulator libraries and enabling technologies such as delivery capsids. It was founded by individuals affected by Duchenne and is purpose-built to advance treatments for neuromuscular and cardiac diseases. All candidates remain in preclinical or clinical development and none are approved for commercial sale.

Revenue drivers

• SGT-003 (Duchenne) — Lead clinical-stage gene therapy candidate for Duchenne muscular dystrophy; has received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations, plus European Commission Orphan Drug designation and a UK Innovation Passport. No product revenue has been generated.
• SGT-212 (Friedreich's ataxia) — Gene therapy candidate for Friedreich's ataxia in clinical development, listed among the company's ongoing programs. Contributes no revenue currently.
• Cardiac candidates (SGT-501, SGT-601) — SGT-501 for CPVT and SGT-601 for TNNT2-mediated dilated cardiomyopathy are cardiac gene therapy candidates in development. No revenue has been recognized from these programs.
• Platform technologies and collaborations — The company is developing capsid libraries and other gene therapy delivery technologies and may pursue collaborations or strategic relationships. No collaboration revenue was reported in the excerpted financials.

Recent performance

Annual revenue was $8.1 million in 2022 and $0.00 in 2018 through 2020, with no product revenue reported. Net losses widened from $72.2 million in 2021 to $174.3 million in 2025. Operating cash flow was negative $156.3 million in 2025, compared with negative $100.0 million in 2024. As of December 31, 2025, the company had an accumulated deficit of $957.8 million. At June 30, 2026, total assets were $420.6 million, total liabilities $46.5 million, shareholder equity $374.1 million, and cash and equivalents $159.4 million.

Strategy

Solid Biosciences is advancing a diverse pipeline across rare neuromuscular and cardiac diseases, with clinical development of SGT-003, SGT-212 and SGT-501. The company aims to build an innovation platform integrating internal capabilities such as a vector core, validated animal models, optimized expression cassettes, novel capsids and regulatory expertise. It also plans to develop innovative libraries of genetic regulators and other enabling technologies intended to impact gene therapy delivery cross-industry. In March 2026, the company entered a securities purchase agreement for 14,973,257 shares and pre-funded warrants to purchase 27,807,482 shares, alongside a registration rights agreement. Management states it expects to incur significant expenses and operating losses for the foreseeable future.

Risks

• No product revenue and recurring losses — The company has incurred significant net losses since inception, with a $174.3 million net loss in 2025 and an accumulated deficit of $957.8 million as of December 31, 2025.
• Capital requirements — Negative operating cash flow of $156.3 million in 2025 and no product revenue mean the company depends on external financing to fund development.
• Clinical and regulatory uncertainty — All candidates, including SGT-003, SGT-212, SGT-501 and SGT-601, remain in development and require regulatory approval that may never be obtained.
• Manufacturing and scalability — The company cites manufacturing capabilities, capacity constraints and the scalability and commercial viability of its manufacturing methods as risks.

Outlook

Management expects to continue incurring significant expenses and operating losses for the foreseeable future and states it could be several years before any commercialized product exists, if ever. The company is continuing to advance its pipeline of candidates, including SGT-003, SGT-212 and SGT-501, and is pursuing platform technologies and potential collaborations. It has not provided a timeline for profitability or product approval in the excerpted materials.